DONADIO, ELEONORA MARIA
 Distribuzione geografica
Continente #
NA - Nord America 178
AS - Asia 124
EU - Europa 99
SA - Sud America 16
AF - Africa 10
Totale 427
Nazione #
US - Stati Uniti d'America 174
SG - Singapore 55
CN - Cina 36
SE - Svezia 26
IE - Irlanda 24
HK - Hong Kong 17
DE - Germania 15
IT - Italia 13
BR - Brasile 11
VN - Vietnam 7
FI - Finlandia 5
GB - Regno Unito 5
FR - Francia 4
NL - Olanda 4
ZA - Sudafrica 4
DZ - Algeria 2
KE - Kenya 2
MX - Messico 2
PY - Paraguay 2
AM - Armenia 1
AR - Argentina 1
AZ - Azerbaigian 1
CA - Canada 1
EC - Ecuador 1
EG - Egitto 1
GT - Guatemala 1
HU - Ungheria 1
ID - Indonesia 1
IL - Israele 1
IN - India 1
JP - Giappone 1
LK - Sri Lanka 1
PK - Pakistan 1
PL - Polonia 1
RU - Federazione Russa 1
SN - Senegal 1
TR - Turchia 1
VE - Venezuela 1
Totale 427
Città #
Chandler 39
Singapore 33
Ashburn 30
Dublin 24
Santa Clara 20
Beijing 19
Hong Kong 17
Munich 10
Parma 7
Dallas 6
Shanghai 6
Los Angeles 5
Ann Arbor 4
Boardman 4
Bremen 4
Johannesburg 4
New York 4
Princeton 4
Boston 3
Ho Chi Minh City 3
Milan 3
Turku 3
Des Moines 2
Hanoi 2
Helsinki 2
Mexico City 2
Nairobi 2
Phoenix 2
Salvador 2
The Dalles 2
Wilmington 2
Algiers 1
Amambai 1
Ankara 1
Araruama 1
Asunción 1
Baku 1
Bandung 1
Budapest 1
Buffalo 1
Catarina 1
Changsha 1
Charlotte 1
Colombo 1
Columbus 1
Council Bluffs 1
Da Nang 1
Dakar 1
Didouche Mourad 1
Fairfield 1
Fortaleza 1
Guatemala City 1
Hampton 1
Islamabad 1
La Guaira 1
Leme 1
Luque 1
Matias Barbosa 1
Miami 1
Paraná 1
Poplar 1
Port Said 1
Pune 1
Quito 1
Redwood City 1
Rio Bonito 1
Rockville 1
Rostov-on-Don 1
São José do Rio Preto 1
Taiyuan 1
Tampa 1
Tel Aviv 1
Timon 1
Tokyo 1
Toronto 1
Warsaw 1
Wigan 1
Woodbridge 1
Xi'an 1
Yerevan 1
Totale 319
Nome #
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients 118
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: Final results of the phase III randomized Short-HER study 112
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies 112
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial 89
Totale 431
Categoria #
all - tutte 1.709
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.709


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20215 0 0 0 0 0 2 1 1 0 0 1 0
2021/202214 0 0 1 2 0 0 0 0 2 1 1 7
2022/2023106 11 15 6 10 11 12 2 8 26 0 1 4
2023/202428 1 3 0 1 2 4 3 2 2 2 2 6
2024/2025105 1 6 8 4 9 15 0 5 8 14 11 24
2025/2026144 33 16 21 26 42 6 0 0 0 0 0 0
Totale 431